Semiquantitative 67Ga scintigraphy as an indicator of response to and prognosis after corticosteroid treatment in idiopathic interstitial pneumonia

Journal of Nuclear Medicine

Volumn 46, Issue 9, 2005, Pages 1421-1426

  Grijm, Karin ^a,b   Verberne, Hein J ^a   Krouwels, Frans H ^a   Weller, Frank R ^a   Jansen, Henk M ^a   Bresser, Paul ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Interstitial pneumonia; Noninvasive techniques; Pulmonary 67Ga scintigraphy; Pulmonary fibrosis; Steroids

Indexed keywords

GALLIUM 67; METHYLPREDNISOLONE; PREDNISOLONE; CORTICOSTEROID; DIAGNOSTIC AGENT; GALLIUM; GALLIUM CHLORIDE; IMMUNOSUPPRESSIVE AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FUNCTION; LUNG LAVAGE; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SCINTIGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOSPITALIZATION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADRENAL CORTEX HORMONES; FEMALE; GALLIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROGNOSIS; PULMONARY FIBROSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 27744563900     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. American Thoracic Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.
2. Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 1976;298:801-809.
3. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest. 1998;113:396-400.
4. Gay SE, Kazerooni EA, Toews GE, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998;57:1063-1072.
5. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980;35:171-180.
6. King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164:1025-1032.
7. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162:2213-2217.
8. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1999;160:899-905.
9. Ramsay SC, Yeates MG, Burke WM, Bryant DH, Morgan GW, Breit SN. Quantative pulmonary gallium scanning in interstitial lung disease. Eur J Nucl Med. 1992;19:80-85.
10. 67Gallium citrate lung scans in interstitial lung disease. Chest. 1976;69(2 suppl):266-268.
11. Line BR, Fulmer JD, Reynolds HY, et al. Gallium-67 citrate scanning in the staging of idiopathic pulmonary fibrosis: correlation with physiologic and morphologic features and bronchoalveolar lavage. Am Rev Respir Dis. 1978;118: 355-365.
12. Vergnon JM, Lahneche B, Ripoll JP, Pages J, Chauvot P, Brune J. Analysis by broncho-alveolar lavage of the pulmonary uptake of gallium 67 in idiopathic diffuse interstitial fibrosis and sarcoidosis [in French]. Rev Mal Respir. 1987;4: 85-93.
13. Fujishima S, Kanazawa M, Yamasawa F, Kubo A, Hashimoto S, Yokoyama T. Clinical significance of gallium-67 scintigraphy in assessing pulmonary lesions of sarcoidosis and idiopathic pulmonary fibrosis. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30:435-440.
14. Vanderstappen M, Mornex JF, Lahneche B, et al. Gallium-67 scanning in the staging of cryptogenic fibrosing alveolitis and hypersensitivity pneumonitis. Eur Respir J. 1988;1:517-522.
15. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976;85:769-788.
16. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax. 1980;35: 593-599.
17. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 suppl, pt 1):1301-1315.
18. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 suppl, pt 1):646-664.
19. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal function trends. Am J Respir Crit Care Med. 2003;168:531-537.
20. 67Ga scintigraphy in the evaluation of pulmonary sarcoidosis. Eur J Nucl Med. 1983;8:351-353.
21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
22. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity): Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:41-52.
23. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144:291-296.
24. Jansen HM, Schutte AJH, Elema JD, et al. Local immune complexes and inflammatory response in patients with interstitial disorders associated with collagen vascular diseases. Clin Exp Immunol. 1984;56:311-320.
25. 67gallium incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med. 1974;83:489-495.
26. Veeraraghavan S, Nicholson AG, Wells AU. Lung fibrosis: new classifications and therapy. Curr Opin Rheumatol. 2001;13:500-504.
27. Noble PW. Idiopathic pulmonary fibrosis: new insights into classification and pathogenesis usher in a new era therapeutic approaches. Am J Respir Cell Mol Biol. 2003;29(3 suppl):S27-S31.
28. Maeyama T, Kuwano K, Kawasaki M, et al. Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17:180-189.
29. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Investig. 1999;104: 13-19.
30. 67gallium. Eur J Nucl Med. 1987;13(suppl):24-36.
31. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med. 1984;19:154-166.